Europe Rare Diseases Treatment Market Size, Share & Industry Trends Analysis Report By Distribution Channel (Specialty Pharmacy, Hospital Pharmacy, and Online Pharmacy), By Route of Administration, By Therapeutic Area, By Country and Growth Forecast, 2022 - 2028
The Europe Rare Diseases Treatment Market would witness market growth of 12% CAGR during the forecast period (2022-2028).
Manufacturers of the new drugs benefit from tax breaks, quick approvals, and other research grants, allowing for much more innovation. Product development can lead to technological products and medical or pharmaceutical innovations that can be utilized to expand into new markets. The general public is conscious of such rare diseases, and this awareness is growing as a result of the government's efforts.
Adding to this scenario, cost recovery strategies in developed nations are driving up the demand for rare disease treatments. Ignorance of rare diseases can be more expensive than research aimed at increasing knowledge. Rare genetic diseases frequently affect patients at a young age and reduce life expectancy, so affected individuals may need health care for the rest of their lives.
The adoption of more advanced home healthcare equipment, as well as the launch of innovative value-based payment and service models, have created a profitable investment opportunity in U.K. healthcare. As the region's healthcare industry expands, the regional market players are contributing heavily in the development of advanced rare diseases treatment in the region. With R&D corporation tax relief, the UK encourages investment as well as rewards innovation in the healthcare life sciences & technology sector. As a result of this, vendors are increasingly investing in the Europe region.
The Germany market dominated the Europe Rare Diseases Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $16,772 million by 2028. The UK market would experience a CAGR of 11.1% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 12.9% during (2022 - 2028).
Based on Distribution Channel, the market is segmented into Specialty Pharmacy, Hospital Pharmacy, and Online Pharmacy. Based on Route of Administration, the market is segmented into Injectable, Oral, and Others. Based on Therapeutic Area, the market is segmented into Cancer, Cardiovascular Conditions, Infectious Diseases, Musculoskeletal Conditions, Endocrine Disorders, Metabolic Disorders, Hematologic Disorders, Neurological Conditions, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Merck Group, Bristol Myers Squibb Company, Pfizer, Inc., AstraZeneca PLC, Takeda Pharmaceutical Company Limited and PTC Therapeutics, Inc.
Scope of the Study
Market Segments covered in the Report:
By Drug Type
- Biologics
- Biosimilar
- Small Molecule
- Specialty Pharmacy
- Hospital Pharmacy
- Online Pharmacy
- Injectable
- Oral
- Others
- Cancer
- Cardiovascular Conditions
- Infectious Diseases
- Musculoskeletal Conditions
- Endocrine Disorders
- Metabolic Disorders
- Hematologic Disorders
- Neurological Conditions
- Others
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- AbbVie, Inc.
- F. Hoffmann-La Roche Ltd.
- Bayer AG
- Novartis AG
- Merck Group
- Bristol Myers Squibb Company
- Pfizer, Inc.
- AstraZeneca PLC
- Takeda Pharmaceutical Company Limited
- PTC Therapeutics, Inc.
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
- Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 Europe Rare Diseases Treatment Market, by Drug Type
- 1.4.2 Europe Rare Diseases Treatment Market, by Distribution Channel
- 1.4.3 Europe Rare Diseases Treatment Market, by Route of Administration
- 1.4.4 Europe Rare Diseases Treatment Market, by Therapeutic Area
- 1.4.5 Europe Rare Diseases Treatment Market, by Country
- 1.5 Methodology for the research
- Chapter 2. Market Overview
- 2.1 Introduction
- 2.1.1 Overview
- 2.1.1.1 Market Composition & Scenario
- 2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints
- Chapter 3. Competition Analysis - Global
- 3.1 KBV Cardinal Matrix
- 3.2 Recent Industry Wide Strategic Developments
- 3.2.1 Partnerships, Collaborations and Agreements
- 3.2.2 Acquisition and Mergers
- 3.2.3 Approvals and Trials
- 3.3 Top Winning Strategies
- 3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
- 3.3.2 Key Strategic Move: (Acquisitions and Mergers: 2018, Jul – 2022, Aug) Leading Players
- Chapter 4. Europe Rare Diseases Treatment Market by Drug Type
- 4.1 Europe Biologics Market by Country
- 4.2 Europe Biosimilar Market by Country
- 4.3 Europe Small Molecule Market by Country
- Chapter 5. Europe Rare Diseases Treatment Market by Distribution Channel
- 5.1 Europe Specialty Pharmacy Market by Country
- 5.2 Europe Hospital Pharmacy Market by Country
- 5.3 Europe Online Pharmacy Market by Country
- Chapter 6. Europe Rare Diseases Treatment Market by Route of Administration
- 6.1 Europe Injectable Market by Country
- 6.2 Europe Oral Market by Country
- 6.3 Europe Others Market by Country
- Chapter 7. Europe Rare Diseases Treatment Market by Therapeutic Area
- 7.1 Europe Cancer Market by Country
- 7.2 Europe Cardiovascular Conditions Market by Country
- 7.3 Europe Infectious Diseases Market by Country
- 7.4 Europe Musculoskeletal Conditions Market by Country
- 7.5 Europe Endocrine Disorders Market by Country
- 7.6 Europe Metabolic Disorders Market by Country
- 7.7 Europe Hematologic Disorders Market by Country
- 7.8 Europe Neurological Conditions Market by Country
- 7.9 Europe Others Market by Country
- Chapter 8. Europe Rare Diseases Treatment Market by Country
- 8.1 Germany Rare Diseases Treatment Market
- 8.1.1 Germany Rare Diseases Treatment Market by Drug Type
- 8.1.2 Germany Rare Diseases Treatment Market by Distribution Channel
- 8.1.3 Germany Rare Diseases Treatment Market by Route of Administration
- 8.1.4 Germany Rare Diseases Treatment Market by Therapeutic Area
- 8.2 UK Rare Diseases Treatment Market
- 8.2.1 UK Rare Diseases Treatment Market by Drug Type
- 8.2.2 UK Rare Diseases Treatment Market by Distribution Channel
- 8.2.3 UK Rare Diseases Treatment Market by Route of Administration
- 8.2.4 UK Rare Diseases Treatment Market by Therapeutic Area
- 8.3 France Rare Diseases Treatment Market
- 8.3.1 France Rare Diseases Treatment Market by Drug Type
- 8.3.2 France Rare Diseases Treatment Market by Distribution Channel
- 8.3.3 France Rare Diseases Treatment Market by Route of Administration
- 8.3.4 France Rare Diseases Treatment Market by Therapeutic Area
- 8.4 Russia Rare Diseases Treatment Market
- 8.4.1 Russia Rare Diseases Treatment Market by Drug Type
- 8.4.2 Russia Rare Diseases Treatment Market by Distribution Channel
- 8.4.3 Russia Rare Diseases Treatment Market by Route of Administration
- 8.4.4 Russia Rare Diseases Treatment Market by Therapeutic Area
- 8.5 Spain Rare Diseases Treatment Market
- 8.5.1 Spain Rare Diseases Treatment Market by Drug Type
- 8.5.2 Spain Rare Diseases Treatment Market by Distribution Channel
- 8.5.3 Spain Rare Diseases Treatment Market by Route of Administration
- 8.5.4 Spain Rare Diseases Treatment Market by Therapeutic Area
- 8.6 Italy Rare Diseases Treatment Market
- 8.6.1 Italy Rare Diseases Treatment Market by Drug Type
- 8.6.2 Italy Rare Diseases Treatment Market by Distribution Channel
- 8.6.3 Italy Rare Diseases Treatment Market by Route of Administration
- 8.6.4 Italy Rare Diseases Treatment Market by Therapeutic Area
- 8.7 Rest of Europe Rare Diseases Treatment Market
- 8.7.1 Rest of Europe Rare Diseases Treatment Market by Drug Type
- 8.7.2 Rest of Europe Rare Diseases Treatment Market by Distribution Channel
- 8.7.3 Rest of Europe Rare Diseases Treatment Market by Route of Administration
- 8.7.4 Rest of Europe Rare Diseases Treatment Market by Therapeutic Area
- Chapter 9. Company Profiles
- 9.1 AbbVie, Inc.
- 9.1.1 Company Overview
- 9.1.2 Financial Analysis
- 9.1.3 Regional Analysis
- 9.1.4 Research & Development Expense
- 9.1.5 Recent strategies and developments:
- 9.1.5.1 Partnerships, Collaborations, and Agreements:
- 9.2 F. Hoffmann-La Roche Ltd.
- 9.2.1 Company Overview
- 9.2.2 Financial Analysis
- 9.2.3 Segmental and Regional Analysis
- 9.2.4 Research & Development Expense
- 9.2.5 Recent strategies and developments:
- 9.2.5.1 Acquisition and Mergers:
- 9.3 Bayer AG
- 9.3.1 Company Overview
- 9.3.2 Financial Analysis
- 9.3.3 Segmental and Regional Analysis
- 9.3.4 Research & Development Expense
- 9.4 Novartis AG
- 9.4.1 Company Overview
- 9.4.2 Financial Analysis
- 9.4.3 Segmental and Regional Analysis
- 9.4.4 Research & Development Expense
- 9.4.5 Recent strategies and developments:
- 9.4.5.1 Approval and Trails:
- 9.5 Merck Group
- 9.5.1 Company Overview
- 9.5.2 Financial Analysis
- 9.5.3 Segmental and Regional Analysis
- 9.5.4 Research & Development Expense
- 9.5.5 Recent strategies and developments:
- 9.5.5.1 Acquisition and Mergers:
- 9.6 Bristol Myers Squibb Company
- 9.6.1 Company Overview
- 9.6.2 Financial Analysis
- 9.6.3 Regional Analysis
- 9.6.4 Research & Development Expenses
- 9.6.5 Recent strategies and developments:
- 9.6.5.1 Acquisition and Mergers:
- 9.7 Pfizer, Inc.
- 9.7.1 Company Overview
- 9.7.2 Financial Analysis
- 9.7.3 Regional & Segmental Analysis
- 9.7.4 Research & Development Expense
- 9.7.5 Recent strategies and developments:
- 9.7.5.1 Partnerships, Collaborations, and Agreements:
- 9.7.5.2 Acquisitions and Mergers:
- 9.8 AstraZeneca PLC
- 9.8.1 Company Overview
- 9.8.2 Financial Analysis
- 9.8.3 Regional Analysis
- 9.8.4 Research & Development Expenses
- 9.8.5 Recent strategies and developments:
- 9.8.5.1 Partnerships, Collaborations, and Agreements:
- 9.8.5.2 Acquisition and Mergers:
- 9.8.5.2 Takeda Pharmaceutical Company Limited
- 9.9.1 Company Overview
- 9.9.2 Financial Analysis
- 9.9.3 Regional Analysis
- 9.9.4 Research & Development Expense
- 9.9.5 Recent strategies and developments:
- 9.9.5.1 Partnerships, Collaborations, and Agreements:
- 9.9.5.2 Acquisition and Mergers:
- 9.10. PTC Therapeutics, Inc.
- 9.10.1 Company Overview
- 9.10.2 Financial Analysis
- 9.10.3 Regional Analysis
- 9.10.4 Research & Development Expenses
- 9.10.5 Recent strategies and developments:
- 9.10.5.1 Partnerships, Collaborations, and Agreements:
- 9.10.5.2 Acquisition and Mergers:
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook